The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
RAS Point Mutations and PAX8-PPARγ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma
Abstract
A series of 88 conventional follicular and Hürthle cell thyroid tumors were analyzed for RAS mutations and PAX8-PPAR gamma rearrangements using molecular methods and for galectin-3 and HBME-1 expression by immunohistochemistry. A novel LightCycler technology-based method was developed to detect point mutations in codons 12/13 and 61 of the H-RAS, K-RAS, and N-RAS genes. Forty-nine percent of conventional follicular carcinomas had RAS mutations, 36% had PAX8-PPAR gamma rearrangement, and only one (3%) had both. In follicular adenomas, 48% had RAS mutations, 4% had PAX8-PPAR gamma rearrangement, and 48% had neither. Follicular carcinomas with PAX8-PPAR gamma typically showed immunoreactivity for galectin-3 but not for HBME-1, tended to present at a younger patient age and be smaller size, and were almost always overtly invasive. In contrast, follicular carcinomas with RAS mutations most often displayed an HBME-1-positive/galectin-3-negative immunophenotype and were either minimally or overtly invasive. Hürthle cell tumors infrequently had PAX8-PPAR gamma rearrangement or RAS mutations. These results suggest that conventional follicular thyroid carcinomas develop through at least two distinct and virtually nonoverlapping molecular pathways initiated by either RAS point mutation or PAX8-PPAR gamma rearrangement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Firminger, H. I. (1968) · Armed Forces Institute of Pathology eBooks · Cited by 3,044
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Management of a Solitary Thyroid Nodule
Desforges, J. F., & Mazzaferri, E. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280807 · Cited by 1,412
Continuous Fluorescence Monitoring of Rapid Cycle DNA Amplification
Wittwer, C. T., Herrmann, M. G., Moss, A. A., & Rasmussen, R. P. (2013) · BioTechniques · doi:10.2144/000114043 · Cited by 1,274
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Self-citationRosaí, J., Carcangiu, M. L., & DeLellis, R. A. (1992) · Armed Forces Institute of Pathology eBooks · Cited by 492
High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.
Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Williams, E. D., Goyns, M. H., Stringer, B. M. J., & Wynford‐Thomas, D. (1989) · PubMed · Cited by 417
Bartolazzi, A., Gasbarri, A., Papotti, M., Bussolati, G., Lucante, T., Khan, A., Inohara, H., Marandino, F., Orlandi, F., Nardi, F., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04817-0 · Cited by 409
Point Mutations of Ras Oncogenes are an Early Event in Thyroid Tumorigenesis
Namba, H., Rubin, S. A., & Fagin, J. A. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-10-1474 · Cited by 356
PAX8-PPARγ Rearrangement in Thyroid Tumors: RT-PCR and Immunohistochemical Analyses
Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G., & Nikiforov, Y. E. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200208000-00006 · Cited by 349
Self-citationImmunohistochemical Diagnosis of Papillary Thyroid Carcinoma
Cheung, C. C., Ezzat, S., Freeman, J. L., Rosen, I. B., & Asa, S. L. (2001) · Modern Pathology · doi:10.1038/modpathol.3880312 · Cited by 335
Xu, X., El‐Naggar, A. K., & Lotan, R. (1995) · Europe PMC (PubMed Central) · Cited by 332
Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas
Marques, A. R., Espadinha, C., Catarino, A. L., Moniz, S., Pereira, T., Sobrinho, L. G., & Leite, V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8756 · Cited by 305
Presence of mutations in all three ras genes in human thyroid tumors.
Suarez, H. G., Ja, D. V., Severino, M. E., Caillou, B., Schlumberger, M. J., Tubiana, M., Parmentier, C., & Monier, R. (1990) · PubMed · Cited by 262
Activated ras oncogenes in human thyroid cancers.
Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Farr, C. J., Hughes, D., Padua, R. A., Thurston, V., Williams, E. D., & Wynford‐Thomas, D. (1988) · PubMed · Cited by 233
Prevalence of Ras mutations in thyroid neoplasia
Esapa, C. T., Johnson, S. J., Kendall‐Taylor, P., Lennard, T. W. J., & Harris, P. E. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00704.x · Cited by 220
Basolo, F., Pisaturo, F., Pollina, L. E., Fontanini, G., Elisei, R., Molinaro, E., Iacconi, P., Miccoli, P., & Pacini, F. (2000) · Thyroid · doi:10.1089/thy.2000.10.19 · Cited by 155
Galectin-3 and CD44v6 Isoforms in the Preoperative Evaluation of Thyroid Nodules
Gasbarri, A., Martegani, M. P., Prete, F. D., Lucante, T., Natali, P. G., & Bartolazzi, A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3494 · Cited by 150
Sack, M. J., Astengo-Osuna, C., Lin, B. T.-Y., et al. (1997) · PubMed · Cited by 135
Inhibitory Effects of Peroxisome Proliferator-Activated Receptor γ on Thyroid Carcinoma Cell Growth
Martelli, M. L., Iuliano, R., Pera, I. L., Samà, I., Monaco, C., Cammarota, S., Kroll, T. G., Chiariotti, L., Santoro, M. M., & Fusco, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-012054 · Cited by 135
Self-citationNikiforov, Y. E., Nikiforova, M. N., Gnepp, D. R., & Fagin, J. A. (1996) · PubMed · Cited by 127
Self-citationRole of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin
Motoi, N., Sakamoto, A., Yamochi, T., Horiuchi, H., Motoi, T., & Machinami, R. (2000) · Pathology - Research and Practice · doi:10.1016/s0344-0338(00)80015-1 · Cited by 106
Grebe, S. K. G., McIver, B., HAY, I. D., Wu, P. S.-C., Maciel, L. M. Z., Drabkin, H. A., Goellner, J. R., Grant, C. S., Jenkins, R. B., & Eberhardt, N. L. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3684 · Cited by 103
Jones, C. J., Kipling, D., Morris, M., Hepburn, P., Skinner, J., Bounacer, A., Wyllie, F. S., Ivan, M., Bartek, J., Wynford-Thomas, D., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5690-5699.2000 · Cited by 89
Multiplex PCR by multicolor fluorimetry and fluorescence melting curve analysis
Elenitoba‐Johnson, K. S. J., Bohling, S. D., Wittwer, C. T., & King, T. C. (2001) · Nature Medicine · doi:10.1038/84708 · Cited by 82
Segev, D. L., Saji, M., Phillips, G., Westra, W. H., Takiyama, Y., Piantadosi, S., Smallridge, R. C., Nishiyama, R. H., Udelsman, R., & Zeiger, M. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4882 · Cited by 49
Partial transformation of human thyroid epithelial cells by mutant Ha-ras oncogene.
Lemoine, N. R., Staddon, S. L., BOND, J. A., Wyllie, F. S., Shaw, J. J., & Wynford‐Thomas, D. (1990) · PubMed · Cited by 49
Deletion of 3p25→pter in a primary follicular thyroid carcinoma and its metastasis
Roque, L., Castedo, S. M. M. J., Clode, A. L., & Soares, J. (1993) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870080311 · Cited by 45
Santelli, G., de Franciscis, V., Portella, G., Chiappetta, G., D’Alessio, A. M., Califano, D., Rosati, R., Mineo, A., Monaco, C., & Manzo, G. (1993) · PubMed · Cited by 44
Distinguishing Benign from Malignant Thyroid Lesions: Galectin 3 as the Latest Candidate
Lloyd, R. V. (2001) · Endocrine Pathology · doi:10.1385/ep:12:3:255 · Cited by 31
Novel and nondetected human signaling protein polymorphisms
Lynch, R. A., Wagoner, L. E., Li, S., Sparks, L., Molkentin, J. D., & Dorn, G. W. (2002) · Physiological Genomics · doi:10.1152/physiolgenomics.00030.2002 · Cited by 18
Self-citation
Cited by
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Overview of the 2022 WHO Classification of Thyroid Neoplasms
Baloch, Z. W., Asa, S. L., Barletta, J. A., Ghossein, R. A., Juhlin, C. C., Jung, C. K., LiVolsi, V. A., Papotti, M. G., Sobrinho-Simões, M., Tallini, G., et al. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09707-3 · Cited by 1,158
Self-citationMolecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Self-citationInternational Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Biologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Metadata
- Authors
- Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-05
- Volume
- 88
- Issue
- 5
- Pages
- 2318-2326
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2087916660
- Cited by
- 713
- References
- 31
- FWCI
- 19.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.